MA-5 in a Gaucher disease mouse model and patient-derived microglia: mitochondrial and transcriptomic effects
In a Gaucher disease mouse model and patient-derived iPSC microglia, the mitochondria-targeting compound MA-5 raised ATP, preserved mitochondrial cristae, limited mtDNA release and suppressed inflammatory signaling; it also prolonged survival and reversed accelerated transcriptomic aging, most prominently in microglia. [1]
Automatic summary · not editorially reviewed
The key findings
In a Gaucher disease mouse model, marked mitochondrial cristae disorganization and mitochondrial DNA release accompanied activation of the cGAS–STING and NLRP3 inflammasome pathways and inflammatory microglial activation. [1]
In the Gaucher mouse model and patient-derived iPSC microglia, MA-5 increased ATP levels, preserved cristae integrity, limited mtDNA release and suppressed cGAS–STING and NLRP3 inflammasome signaling. [1]
MA-5 prolonged survival and reversed accelerated transcriptomic aging across multiple brain cell types, with particularly prominent effects in microglia. [1]
The source at a glance
- Study type / format
- Preclinical study in a mouse model and patient-derived cells (abstract only)
- Population / context
- A Gaucher disease mouse model, patient-derived iPSC microglia and patients with Gaucher disease (galectin-3 measurement).
- Summary based on
- Study abstract
- Publication status
- Preprint · peer-review status not confirmed
- Original publication
- September 14, 2026
Gaucher mouse model: mitochondrial damage and inflammation
The abstract describes a Gaucher disease mouse model with marked disorganization of mitochondrial cristae and release of mitochondrial DNA. This was accompanied by activation of the cGAS–STING and NLRP3 inflammasome pathways and subsequent inflammatory microglial activation. Galectin-3 in the blood was also elevated in both the model mice and patients with Gaucher disease, which the authors present as support for its possible relevance as a systemic marker of disease-associated inflammation. These are described associations in a model and in patients, not evidence that mitochondrial damage causes the inflammatory changes.
Supporting source [1]
MA-5 effects in mouse model and patient-derived microglia
MA-5 is described as a mitochondria-targeting compound that interacts with mitofilin/MIC60 in the inner mitochondrial membrane and enhances ATP production. In the Gaucher mouse model and in patient-derived iPSC microglia, MA-5 increased ATP levels, preserved cristae integrity, limited mtDNA release and suppressed cGAS–STING and NLRP3 inflammasome signaling. Thereby it attenuated microglial innate immune activation and galectin-3 expression. MA-5 also prolonged survival and reversed accelerated transcriptomic aging across multiple brain cell types, with particularly prominent effects in microglia. These are preclinical and cell-based findings; they do not show human lifespan or clinical benefits.
Supporting source [1]
Liver findings and abstract-only scope
In the liver, Gaucher disease was similarly associated with inflammatory, stress-related and aging-associated transcriptional changes. MA-5 improved liver function, restored mitochondrial morphology, suppressed inflammatory and stress responses, restored metabolic programs and reduced transcriptomic age. The abstract does not report sample sizes, follow-up durations, comparator groups or statistical uncertainty, and the full text was not reviewed. The proposed therapeutic use for Gaucher disease, other lysosomal storage disorders and diseases with mitochondrial dysfunction, chronic inflammation and pathological accumulation remains a proposal, not a validated treatment.
Supporting source [1]
How to interpret this
This explainer is based only on the abstract; the full text was not reviewed. The abstract reports no sample sizes, follow-up durations, comparator groups or statistical uncertainty. Findings come from a Gaucher mouse model and patient-derived iPSC microglia, not from human clinical trials, and do not establish human lifespan or clinical benefits. The proposed therapeutic use remains a proposal.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Abe T, Tongu Y, Kasahara T, Nakamura K, Tyshkovskiy A, Oikawa Y, Matsuhashi T, Numakura C, Fujita R, Kagawa Y, Yu h, Tomita H, Furuyashiki T, Inoue R, Saigusa D, Kujirai R, Matsumoto Y, Tomioka Y, Kakazu E, Shimura M, Sugiyama Y, Watanabe S, Honkura Y, Katori Y, Niizuma K, Endo H, Hashimoto K, Kawabe C, Tokuno H, Kikuchi K, Suzuki C, Sato T, Matsumoto N, Aoki J, Murayama K, Owada Y, Soga T, Sato T, Suzuki T, Toyohara T, OKAZAKI Y, Anderson P, Gladyshev V. · europepmc.org · September 14, 2026